GLP-1 weight loss plateau: does injection timing actually matter?

What did @drjonesdc actually say?

The claim, boiled down: if your weight loss has stalled on GLP-1 medications like semaglutide or tirzepatide, the problem is that you're eating too little, not too much. The solution, according to this creator, is a 36-hour fast followed by higher-calorie, higher-protein days, something they call "strategic refeeding with fasting cycles."

The creator also floated the idea that "about 90% of people" they see fall into what they branded the "Ozempic trap," a state where the medication suppresses appetite so effectively that patients under-eat, slow their metabolism, and stop losing weight. As proof, they cited a single patient who lost 12 pounds in two weeks after months of plateauing. The creator identifies themselves as "Dr. Jones DC," meaning a Doctor of Chiropractic, not a physician, dietitian, or endocrinologist. That context matters when evaluating clinical weight loss advice.

Does the science back this up?

Partially, but the execution here veers into territory that's not well-supported and could be actively harmful. The underlying metabolic adaptation concept has real evidence behind it. The 36-hour fasting protocol as a specific fix, less so.

Metabolic adaptation during caloric restriction is documented. Rosenbaum and Leibel (2010, Journal of Clinical Investigation) showed that sustained caloric deficits reduce resting energy expenditure beyond what body composition changes alone would predict. More recently, Fothergill et al. (2016, Obesity) tracked contestants from The Biggest Loser and found persistent metabolic slowdowns years after weight loss. So yes, eating very little for extended periods can suppress metabolic rate. That part is real.

Where things get shakier: GLP-1 receptor agonists already reduce appetite dramatically, and clinical guidelines from the American Diabetes Association and obesity medicine specialists recommend protein targets and caloric floors specifically to prevent lean mass loss, not 36-hour fasts stacked on top of a drug that already suppresses hunger. Cava et al. (2017, Nutrients) reviewed intermittent fasting and found mixed evidence on metabolic benefits compared to continuous caloric restriction. There is no peer-reviewed trial specifically testing 36-hour fasting cycles combined with GLP-1 therapy.

What did they get wrong (or right)?

Credit where it's due: the general idea that GLP-1 users can under-eat and stall progress is legitimate. Clinicians who specialize in obesity medicine, including those writing in Obesity Medicine Association guidelines, do flag inadequate protein and caloric intake as a real problem on these medications. That's not invented.

But the creator gets several things meaningfully wrong. First, describing metabolism as something that "drops to match those 800,000 calorie intakes" is hyperbolic nonsense used for rhetorical effect, not clinical accuracy. Metabolic adaptation doesn't work like a thermostat perfectly tracking intake. Second, recommending a 36-hour fast for someone already calorie-restricted on a hunger-suppressing medication raises real safety flags, particularly for people with a history of disordered eating, diabetes, or cardiovascular conditions. Third, a single anecdote of "12 pounds in two weeks" is not evidence, and presenting it as proof of a method is textbook misleading health content. Finally, the "90%" figure is completely unverifiable and appears to be invented for emphasis.

What should you actually know?

If you're on a GLP-1 medication and your weight loss has slowed, a conversation with a registered dietitian or your prescribing provider is the right first step, not a 36-hour fast you found on TikTok. Weight loss plateaus on GLP-1 therapy are real and documented. Volpe et al. (2024, Diabetes, Obesity and Metabolism) noted that dose titration, dietary quality, and protein adequacy all influence long-term outcomes on semaglutide.

What the evidence does support: hitting adequate protein targets (generally 1.2 to 1.6 grams per kilogram of body weight, per the International Society of Sports Nutrition position stand), maintaining enough calories to preserve lean mass, and working with your provider on dose adjustments if appropriate. Extended fasting layered on top of a drug that already aggressively suppresses appetite is not a standard clinical recommendation and carries risks that this video does not address at all. The creator links to their bio for consultations. A DC is not a licensed provider for this kind of metabolic advice in most U.S. states.

Bottom line

This video takes a real clinical phenomenon, metabolic adaptation during GLP-1 therapy, and wraps it in an unverified protocol, invented statistics, and a patient anecdote that proves nothing. The 36-hour fast recommendation is not backed by GLP-1-specific trial data and could be harmful for certain populations. Follow your prescribing provider's guidance, not a viral timing trick.